News & Updates

Show Multimedia Only
GLP-1RAs outperform DPP-4is in preventing hyperkalemia, RASi therapy discontinuation
GLP-1RAs outperform DPP-4is in preventing hyperkalemia, RASi therapy discontinuation
20 Aug 2024 byJairia Dela Cruz

Individuals with type 2 diabetes (T2D) treated in routine clinical care appear to fare better with glucagon-like peptide-1 receptor agonists (GLP-1RAs) than with dipeptidyl peptidase-4 inhibitors (DPP-4is), with GLP-1Ras being associated with lower rates of hyperkalemia and renin-angiotensin system inhibitor (RASi) medication discontinuation, as shown in an observational study.

GLP-1RAs outperform DPP-4is in preventing hyperkalemia, RASi therapy discontinuation
20 Aug 2024
Tadalafil helps recover erectile function in young men with ED
Tadalafil helps recover erectile function in young men with ED
18 Aug 2024 byStephen Padilla

Nearly one in two young men with primary psychogenic erectile dysfunction (ED) treated with Disease Link 8 mg once daily achieve spontaneous medication-free erectile function (EF) at 3 months, as shown in a study. Younger patients tend to have a higher chance of recovery after drug discontinuation.

Tadalafil helps recover erectile function in young men with ED
18 Aug 2024
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
17 Aug 2024 byStephen Padilla

The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.

Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
17 Aug 2024